Indivior updates its earnings outlook, shares trade near recent highs

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 22:44.

Indivior (GB00BYZ0C031) stays on the radar of NASDAQ traders as consensus expectations cluster around solid profit growth and an undemanding earnings multiple. Analyst data for the specialty pharma group highlights its position in the opioid-use-disorder treatment niche compared with peers such as Viatris and Teva Pharmaceutical on U.S. exchanges.

What consensus data suggests

Recent compiled data on Indivior points to a forward price-to-earnings range of roughly 6.5x to 7.5x, a marked discount to many specialty pharmaceutical names that often trade between 12x and 15x earnings, according to an overview of the stock’s valuation metrics. That same analysis cites 2025 GAAP net income of about 210 million dollars, sharply above the roughly 7 million dollars reported in 2024, underscoring a strong swing in profitability as the company scales its long-acting injectable therapies.

On the earnings calendar side, data providers track Indivior under the INDV ticker on NASDAQ and list it among smaller-cap healthcare names with upcoming quarterly updates followed by analyst calls and transcript coverage, aligning it with other U.S.-listed pharma issuers. This positions the stock in a segment where single-drug franchises and patent cycles often drive consensus revisions and valuation resets.

How the shares trade technically

On a technical basis, one trading and analytics service shows Indivior shares around 39 to 40 dollars, with a recent quote of approximately 39.30 dollars and a market capitalization near 4.9 billion dollars. The same source notes that the shares trade between an indicated resistance zone at 40.77 dollars and support near 34.14 dollars, placing the stock in a defined trading range used by swing traders.

Momentum indicators on that platform assign Indivior a score of 9.34, ranking it 21st out of 157 companies in the pharmaceuticals group and flagging a constructive short-term setup. A combination of moving averages from the 5-day to the 200-day range shows several buy signals and no active sell signal in this framework, which some systematic traders use as an additional confirmation input when comparing pharma names.

The treatment portfolio behind the stock

Indivior generates most of its revenue from therapies for opioid-use disorder, including the once-monthly injectable formulation marketed as SUBLOCADE, which reached around 856 million dollars in sales in the latest reported year according to a recent analysis of the company’s financial performance. In addition, Indivior sells sublingual buprenorphine combination products and continues to invest in pipeline candidates targeting addiction and related mental health indications.

Where the shares trade today

The Indivior shares (GB00BYZ0C031) most actively change hands on NASDAQ under the INDV ticker and most recently traded around 39.30 dollars, implying a market capitalization close to 4.9 billion dollars on 2026-06-23.

This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer or solicitation to buy or sell any financial instrument. Investors should conduct their own research and consider seeking independent financial advice.